31 October 2019 | 45:31

Arbitration: considerations for life science companies

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

DNA helix
Life sciences & healthcare

Termination, force majeure and frustration – international perspectives on the life sciences sector

17 April 2020
QUICK READ

by Evelyne Friedel

Click here to find out more
Disputes & investigations

Medical devices and managing product liability risks

30 January 2020
Click here to find out more
International arbitration

Arbitration considerations for life science companies

29 September 2019
Click here to find out more